Abstract Search

ea0094p215 | Metabolism, Obesity and Diabetes | SFEBES2023

Trends in the rate of complications and outcomes in DKA management following modifications in JBDS national guidelines-Results from DEKODE study

Abraham Anu , Solomon Alexandra , Birchenough Amy , Cheung Jason , Rengarajan Lakshmi , Hebbar Meghna , Ali Karamat Muhammad , Ahmed Nabeel , De Parijat , Soghal Shamanth , Working group DEKODE , Falowo Durodoluwa

Introduction: Joint British Diabetes Societies Inpatient (JBDS-IP) recommended reducing fixed-rate intravenous insulin infusion (FRIII) rate to 0.05units/kg/hr when blood glucose falls <14 mmol/l to avoid hypoglycaemia during diabetes-related ketoacidosis (DKA).Aim: We studied the impact of guideline change on complications and outcomes of DKA.Methods: We included all DKA episo...

0 shares

ea0099oc12.4 | Oral Communications 12: Diabetes, Obesity, Metabolism and Nutrition | Part II | ECE2024

Characteristics and outcomes of DKA in people taking SGLT2 inhibitors: DEKODE study

Mathur Nitish , Sharma Angelica , Philip Nevil , Rengarajan Lakshmi , Bomphrey Lucy , Abraham Anu , Saraf Sanjay , Dhatariya Ketan , Kempegowda Punith , Working Group Dekode

Background: Although SGLT2 inhibitors (SGLT2-i) have revolutionised the management of diabetes, they are associated with an increased risk of developing diabetic ketoacidosis (DKA). However, there remains a paucity of evidence about the risk factors, management, and outcomes of DKA episodes associated with SGLT2-i therapy. Improved understanding of these factors in order to optimise education, minimise risk, and improve outcomes of DKA episodes in individuals receiving SGLT2-i...

0 shares

Endocrine Abstracts

Trends in the rate of complications and outcomes in DKA management following modifications in JBDS national guidelines-Results from DEKODE study

Characteristics and outcomes of DKA in people taking SGLT2 inhibitors: DEKODE study

BiosciAbstracts